Unfortunately, the only clinical trial incorporating a patient with advanced NSCLC could not describe objective anti-tumor effects after anti-EPHA2 DS-8895a antibody administration, hence questioning the results of the preclinical studies. Here, EPHA2 is linked to neoplasm.